Diabetes Health Type 1: Oral insulin Pill Proves Feasible

October 8, 2021By

Diabetes Health Staff

Italian researchers have developed a fourth method of delivering insulin to people with type 1 diabetes. An ingestible capsule, filled with insulin, moves along the digestive system until it “docks” with an implanted device that uses magnetism to draw the capsule to it. A built-in needle empties the pill of its insulin load. The capsule is then easily excreted during a regular bowel movement.

Currently there are three ways to supply insulin to people with diabetes: 1) injection via syringes; 2) dosing via an external insulin pump; and 3) dosing via an internal pump that is resupplied through an embedded port on the body.

Each method has its drawbacks. Syringes can cause redness and swelling at the points of injection, and users’ skins can become tough from too many injections at the same site.

External insulin pumps can also cause redness and swelling, and in extreme cases infections.

An internal pouch connected to the digestive system needs to be replenished through a port in the abdomen. Although ports have been used for a long time, there is still a danger of infection or swelling.

This fourth method, which has been tested extensively on pigs, is not quite ready to extend to trials involving humans. If it proves feasible, it will provide a long hoped for a successful workaround of a barrier to insulin treatment that has baffled many diabetes researchers and physicians over the years: How can you get an oral insulin past the fierce acids of the digestive system? Insulin has a relatively delicate molecular structure that can easily be torn apart in any direct encounter with the digestive system.

Source:

National Institutes of Health Research Report Insulin Pill.docx

The post Diabetes Health Type 1: Oral insulin Pill Proves Feasible appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , , ,

Lilly Announces Call for Leonard Award Nominations as Part of Global Initiative Celebrating 100 Years of Insulin

July 6, 2021By

Leonard Award program recognizes innovation and positive achievements in the diabetes community 

Lilly to give $ 100,000 to Life for a Child in recognition of five Award winners 

INDIANAPOLIS, June 24, 2021 – In honor of the 100th anniversary of the discovery of insulin, Eli Lilly and Company (NYSE: LLY) today launched the Leonard Award to recognize diverse champions dedicated to advancing diabetes management through innovative thinking and novel approaches. Nominations are being accepted now until August 31, 2021 at Lilly.com/LeonardAward. 

The Leonard Award is inspired by the life of Leonard Thompson, the first person with diabetes to be treated with insulin in 1922, and looks to celebrate ongoing achievements in the diabetes community. The Award is open to eligible participants from the following categories: 

  • • Teen/young adult:18- to 25-year-old living with diabetes or with a strong personal connection to someone impacted by diabetes 
  • • Advocate/advocacy professional:Active advocate for people with diabetes, either through personal channels or with an established organization 
  • • Endocrinologist/primary care physician:Health care professional specializing in endocrinology or who acts as a primary care physician to people with diabetes 
  • • Diabetes educator/nurse:Diabetes educator and/or nurse specializing in the care of people with diabetes 
  • • Researcher:Research professional dedicated to research in the field of diabetes care (therapeutics, technology or otherwise) 

“The Leonard Award will recognize a variety of strides made in diabetes management, while looking ahead to future, and continued, innovations,” said Leonard Glass, M.D., F.A.C.E., vice president of Lilly Diabetes Global Medical Affairs. “Each submission to the Leonard Award will represent the strength and dedication of a broad community, and we are eager to hear from individuals who have made a positive impact through their commitment to people living with diabetes.” 

Five winners – one from each category – will be selected, and Lilly will give $ 20,000 in recognition of each winner ($ 100,000 total) to Life for a Child, a non-profit organization that provides access to care, education, and lifesaving medicines and supplies to children and young people with type 1 diabetes in less-resourced countries. 

“We’re honored to receive such a donation from Lilly and look forward to learning more about the individuals who are addressing important needs within the diabetes community. This donation supports our shared vision to build a healthier world and continued mission of supporting children and youth with type 1 diabetes,” said Graham Ogle, general manager of Life for a Child. 

To be considered for the Leonard Award, nominees will be required to submit an original project, innovation, or effort – beyond drug or device therapy – that addresses either an important need or challenge in the management of diabetes or aims to support the community. Winners will be selected by an external judges’ panel comprised of esteemed leaders in diabetes care, and Dr. Glass will represent Lilly on that committee. The five Leonard Award winners will be announced in November in advance of World Diabetes Day. 

Nominations and submissions for the Leonard Award are being accepted now through August 31, 2021, at 11:59 p.m. ET. To learn more, nominate someone you know, or complete a submission, visit Lilly.com/LeonardAward. The Leonard Award is free to enter. Official eligibility criteria and terms and conditions can be found on the website. 

About Diabetes 

Approximately 34 million Americans1 (just over 1 in 10) and an estimated 463 million adults worldwide2 have diabetes. Type 2 diabetes is the most common type internationally, accounting for an estimated 90 to 95 percent of all diabetes cases in the United States alone1. Diabetes is a chronic disease that occurs when the body does not properly produce or use the hormone insulin. 

About Lilly Diabetes 

Lilly has been a global leader in diabetes care since 1923, when we introduced the world’s first commercial insulin. Today we are building upon this heritage by working to meet the diverse needs of people with diabetes and those who care for them. Through research, collaboration and quality manufacturing we strive to make life better for people affected by diabetes and related conditions. We work to deliver breakthrough outcomes through innovative solutions—from medicines and technologies to support programs and more. For the latest updates, visit http://www.lillydiabetes.com/ or follow us on Twitter: @LillyDiabetes and Facebook: LillyDiabetesUS. 

About Eli Lilly and CompanyLilly is a global healthcare leader that unites caring with discovery to make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom. P-LLY 

Copyright © 2021 Eli Lilly and Company. All rights reserved. 

Lilly Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about Lilly’s Leonard Award, including its objectives, selection criteria, nomination process, intended donations, and related activities, and reflects Lilly’s current beliefs and expectations. There can be no assurance that the Leonard Award will achieve Lilly’s objectives or that Lilly will execute its strategy as planned. For further discussion of risks and uncertainties relevant to Lilly’s business, see Lilly’s Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. 

1. International Diabetes Federation. IDF Diabetes Atlas, 9th edn.Brussels, Belgium: 2019. Available at: http://www.diabetesatlas.org. 

2. Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2017. Available at: https://www.cdc.

The post Lilly Announces Call for Leonard Award Nominations as Part of Global Initiative Celebrating 100 Years of Insulin appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , , , , , , ,

Diabetes Health Type 1 & 2: Evaluating Mealtime Insulin Treatment Based on Needs and Insights

June 19, 2021By

Sponsored by Lilly Diabetes

People work hard to manage their diabetes and yet, many still struggle to keep blood glucose levels in the target range.1 In fact, according to research, those on intensive insulin treatment*2 still spend more than 30 percent of the time above target blood glucose levels.3 This is of particular concern given the negative health consequences of high blood glucose, including elevated risk for long-term complications such as cardiovascular disease and diabetic retinopathy.4

 

As part of Lilly’s insulin development efforts, we undertook research to better understand the challenges that Americans and Britons living with type 1 diabetes and type 2 diabetes face in managing blood glucose levels on a daily basis. In that study, people treated with a mealtime insulin reported psychological, social, and work/school impacts and physical symptoms.5

 

At Lilly, we believe there is a need to look at a variety of outcomes– including managing blood glucose levels around mealtime – and develop treatment options to address them. Postprandial glucose (blood glucose levels following meals) is an important measure because it impacts, in part, overall A1C management.6 For people with diabetes who are not achieving their target A1C despite reaching their premeal glucose goals, measuring and treating postprandial glucose may help to lower their A1C.6

 

It is with these considerations in mind that we continue to invest in developing products that can better meet the diverse needs of people with diabetes. While insulin development has come a long way, many people with diabetes still struggle with a variety of outcomes, including meeting their target A1C. We hope that providing various insulin options can help people more effectively manage their diabetes.

 

We also understand that cost continues to be top of mind for many living with diabetes. For this reason, we want people who use Lilly insulins and need help affording their medicine to know that we’re here to support them. That’s why we have several affordability options dedicated to helping people with varying insurance circumstances, and individuals can call the Lilly Diabetes Solution Center at (833) 808-1234 to learn more.

 

Click here to learn more about a mealtime insulin option: https://e.lilly/2RA3yKq

*Intensive treatment defined in the Diabetes Control and Complications Trial as having a goal of normalization of blood glucose versus conventional treatment, which is defined as having the goal of clinical well-being.

PP-UR-US-0114 01/2021 ©Lilly USA, LLC 2021. All rights reserved.

References:

  1. Runge, Ava S, et al. Does Time-in-Range Matter? Perspectives From People With Diabetes on the Success of Current Therapies and the Drivers of Improved Outcomes. Clin Diabetes, American Diabetes Association, Apr. 2018, ncbi.nlm.nih.gov/pmc/articles/PMC5898169/.
  2. American Diabetes Association. Implications of the Diabetes Control and Complications Trial. Diabetes Care. 2003. 26(supl1): 25-27. https://doi.org/10.2337/diacare.26.2007.S25
  3. Beck RW, Bergenstal RM, Riddlesworth TD, et al. Validation of Time in Range as an Outcome Measure for Diabetes Clinical Trials. Diabetes Care. 2019; 42(3):400‐405. https://doi.org/10.2337/dc18-1444
  4. Mouri MI, Badireddy M. Hyperglycemia. Sept 2020. Available from: https://www.ncbi.nlm.nih.gov/books/NBK430900/
  5. Poon JL, Gelhorn HL, et al. The Mealtime Insulin Experience: Symptoms and Impacts from the Patient Perspective. Presented at the American Association of Diabetes Educators (AADE) Annual Conference 2019; Aug 9-12.
  6. American Diabetes Association. Postprandial Blood Glucose. Diabetes Care. 2001; 24(4):775-778. https://doi.org/10.2337/diacare.24.4.775

 

The post Diabetes Health Type 1 & 2: Evaluating Mealtime Insulin Treatment Based on Needs and Insights appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , , , , ,

Diabetes Health Type 1: Humalog and Tresiba Insulin is the Perfect Combination for Me

June 17, 2021By

By Claire Lynch

Daniel Hopkins was 28 years old when he was diagnosed last year as Type 1. He told a doctor that he was tired, thirsty and had frequent urination. At first Dan was diagnosed as Type 2 but after two months of not responding well to Metformin nor to low doses of Tresiba, a long-acting insulin, his physicians did some additional tests and determined that he was Type 1.

“My C-peptide test showed very little insulin production and the GAD antibodies test was positive,” Dan explains. “They put me on Humalog, a fast-acting insulin and a larger dose of Tresiba and that combination works well for me. My highest A1C was 14.3 but now it’s down to 6.2.

He’s been using FreeStyle Libre for more than a year and added MiaoMiao and the Spike app to his iPhone.

Dan says, “Checking my blood sugar levels with a finger stick works when I feel low or when I get an alarm signaling high blood sugar levels. The finger sticks are a good way to double check the readings.”

For breakfast Dan often has an egg sandwich on an English muffin, for lunch he has a sandwich or a salad and dinner usually includes some meat or fish plus plenty of fresh vegetables. Dan adds, “I’m trying to incorporate more fruit into my diet but I’m very careful about the sugar and carb content in various fruits.

“When eating out I usually stick to salads. The best low-carb salad dressings I’ve found are ranch or oil and vinegar.”

 

Exercise is important to Dan, a Vermonter, so he says, “I run and skateboard two or three times a week plus hike once or twice a week. No matter what season it is, running while taking in all of the beautiful scenery in this New England state is a great way to get some exercise and blow off some stress.”

Dan and his wife, Lindsey, enjoy going to the coast on long weekends. He works a full-time job as a video editor for a creative agency and he’s also a self-employed wedding cinematographer on the side. His busiest time? June through October when weddings are in full swing.

 

The post Diabetes Health Type 1: Humalog and Tresiba Insulin is the Perfect Combination for Me appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , , ,

AskNadia: Dose A Syringe Length Make Injecting Insulin More Effective?

June 8, 2021By

Hi Nadia: 

How long does my injection syringe need to be, so it is effective? 

Lilly

 

 

Hi Lilly:

 

You’ll notice that diabetes doctors most commonly prescribe a disposable syringe with a 6mm needle length. Compared to the humongous syringes everybody had to use before, the 6mm needle was a breakthrough. 

While the 6mm syringe immensely shortened the length of a needle, it was just as effective as the older needles in delivering medication. Additionally, the short, thin-walled needles are far less painful to use than older needle lengths and widths. 

 

When you are reading the needle gauge, the higher the number, the smaller the needle size. So, if you are looking at the Diabetes Health Syringe chart, a 31 gauge needle will be smaller than a 28 gauge needle.

 

Diabetes medications are not injected directly into the bloodstream. Instead, they are injected under the skin. As a result, syringe needles don’t require great length to be effective. 

 

One of my editors, a type 2, says he most often doesn’t feel his 6mm syringe needles piercing the skin, so he makes sure to push the body of the syringe itself closer to his injection site to make sure the needle is thoroughly in. In your case, follow your healthcare professionals advice on how to inject correctly.

 

Suppose you are asking about the physical length of a syringe, from needle to plunger. In that case, your question relates to the syringe’s capacity. 

 

How much insulin a syringe holds is measured in milliliters. For example, a Trividia 6mm syringe can deliver a ½ milliliter of medicine (doses up to 50 units). A longer syringe will deliver a greater quantity of medication and still provide a mostly pain-free injection with a 6mm needle. 

 

When you injection in a new site, you will usually feel the tiniest pressure against your skin before the needle slides painlessly under your skin. 

 

Fortunately, diabetes researchers and manufacturers have designed syringes to be more comfortable and effective when injecting insulin. 

 

Source:

Diabetes Health Charts

Email Nadia 

Disclaimer:

Nadia’s feedback on your question is in no way intended to initiate or replace your healthcare professional’s therapy or advice. Please check in with your medical team to discuss your diabetes management concerns.

AskNadia and receive her unique perspective on your question.

About Nadia:

AskNadia (ranked #1 by Google) was named “Best Diabetes Blog by Healthline. With 24 nominations, Nadia Al-Samarrie’s efforts have made her stand out as a pioneer and leading patient advocate in the diabetes community.

Nadia was not only born into a family with diabetes but also married into one. As a result, she was propelled at a young age into “caretaker mode,” With her knowledge of the scarcity of resources, support, and understanding for people with diabetes, she co-founded Diabetes Interview, now Diabetes Health magazine.

Under her reign- Diabetes Health magazine was named one of the top 10 magazines to follow in the world for 2018 by Feedspot Blog Reader.

Nadia has been featured on ABC, NBC, CBS, and other major cable networks. In addition, her publications, medical supply business, and website have been cited, recognized, and published in the San Francisco Chronicle, The Wall Street Journal, Ann Landers advice column, former Chrysler chairman Lee Iacocca, Entrepreneur magazine, Houston News, Phili.com, Brand Week, Drug Topics, and many other media outlets.

The post AskNadia: Dose A Syringe Length Make Injecting Insulin More Effective? appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , , ,

AskNadia: Asked to Leave Restaurant for Openly Injecting Insulin

March 21, 2021By

Dear Nadia:
 
I was at a restaurant. After we’d ordered, I tested and dosed. I received a hostile look from a lady at another table. I smiled and said, “I could drop my trousers and inject in my butt, if you’d prefer.” A few moments later a waiter came up and asked me to leave. On the way out I stopped at the hostile lady’s table and said, “I’ve had my hormone replacement for the evening. Enjoy your meal.”
 
I’ve grown less tolerant of the tut-tutting and behind-the-hand comments over the years.What’s your take on what I did?
 
Richard

Dear Richard:

You’ve described and asked about one of the thorniest situations that a person with diabetes can face: What is the “etiquette” for being out in public and needing to inject insulin?

I’m going to split my answer to address two specific topics your question raises.

Public Reaction

An estimated 90 million people in the US are prediabetic. In coming years, the sheer numbers of newly diagnosed people with diabetes will make public injections much more of an occurrence. Right now we are at the point where injecting yourself is a bit of a shock for some people. I would put it on a par with breastfeeding in public (which over the past 30 years has become more and more acceptable).

One part of people’s shock is the aesthetics of a an insulin injection in public. It takes some people by surprise. They’re not used to seeing bare skin under another diner’s shirt—assuming you lifted it to access a patch of skin—or a needle plunging into your skin. The woman’s reaction to your shot may have been a reflexive response to what she was seeing.

So I’m not certain that she was being intentionally rude. However, you perceived it that way and that is what you are asking about.

Dealing With and Reacting to Hostility

That woman’s hostile glare was a teachable moment. But your reaction, “I could drop my trousers and inject in my butt, if you’d prefer,” immediately shifted the blame for hostility from her to you. I understand the years of frustration and turning the other cheek that led you to say what you did, but for the restaurant workers and guests, it was over the top. The restaurant could have handled it a bitt different, if they were more educated on diabetes and medication.

Ironically, the thing you said as you left— “I’ve had my hormone replacement for the evening. Enjoy your meal.” —might have been the better initial response to the woman. Possibly she would have stood down if you had made her understand that injecting yourself in public is a necessity vital to your health. I know that’s a lot to try to convey in just a sentence or two, but it’s one way to slowly educate the general public that people with diabetes are not injecting themselves out of some sick desire to shock or repulse.

Suggestions:

I’d like to suggest three things you can do in preparation for the next time somebody gives you a hostile look. What you are most comfortable with is subjective.

First- Ignore the person. Don’t upset yourself when someone that is ignorant. If the person across from you thinks you are injecting for whatever reason they made up in their head, you cannot control that. Their reaction to you may have nothing to do with you. Just like road rage. 

Kudos for taking your injecting when you needed it. Sometimes people with diabetes will miss an injection because they are more worried about what the people around them are thinking than what they need for their medical condition.

Second, think about buying  an insulin pen. They are far more discreet because the injection needles are hidden, and the pen will not have the same social impact as a syringe. The downside to this suggestion? They are not as cheap as syringes.

Third, I think this is an opportunity for you to communicate with other people living with diabetes to compare notes about how to handle rude people when you’re injecting in public. Ask them for tips or stories about what they’ve found is the most effective way to defuse a situation like the one you were in.

Third, Yelp the restaurant that ejected you. Explain what you said and why. Be civil about it. Your statement may generate a lot of comments and perhaps even a positive response from the restaurant.  I believe the restaurant was reacting to your “butt” remark, not to you injecting in public. Use this charged experience to educate. 

 

When I first started dating my former husband. We went out to a nice restaurant. What impressed me the most about our date is how comfortable he was with injecting at the table. He did not care what people thought, didn’t skip a beat in our conversation while injecting. I was throughly impressed.

I get it, after years of putting up with rude or obnoxious people, this may have been an off day for you as well. My question to you is “why would you give someone that you don’t know so much power of you from a judgmental stare. Your reaction to the person indicates your own discomfort about injecting at the table. 

When I sold diabetes supplies at my medical store in San Francisco, I had one customer who said to me, that she was in love with a man but because he had diabetes she would not marry him. I shared my husband had diabetes.  She looked at me bewildered. ” You mean you knew he had diabetes and you still married him? She asked. Smiling at her ignorant question, I nodded my head and said yes.

 

Disclaimer:

Nadia’s feedback on your question is in no way intended to initiate or replace your healthcare professional’s therapy or advice. Please check in with your medical team to discuss your diabetes management concerns.

AskNadia and receive her unique perspective on your question.

Nadia’s Videos

About Nadia:

Nadia was not only born into a family with diabetes but also married into one. She was propelled at a young age into “caretaker mode,” and with her knowledge of the scarcity of resources, support, and understanding for people with diabetes, co-founded Diabetes Interview, now Diabetes Health magazine.

Nadia has received 19 nominations for her work as a diabetes advocate.
 She has been featured on ABC, NBC, CBS, and other major cable networks. Her publications, medical supply business, and website have been cited, recognized and published in the San Francisco Chronicle, The Wall Street Journal, Ann Landers advice column, former Chrysler chairman Lee Iacocca, Entrepreneur magazine, Houston News, Phili.com, Brand Week, Drug Topics, and many other media outlets.

The post AskNadia: Asked to Leave Restaurant for Openly Injecting Insulin appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , ,

Diabetes Health Type 2: Once-Weekly Basal Insulin                                                                                                                                                                                   

October 20, 2020By

Diabetes Health Staff

Making a chore a habit doesn’t take away the fact it’s a chore. If you’re good at doing the dishes after dinner, that says you’ve accepted the inevitable: The dishes won’t get washed until you perform a necessary chore.

 

If you’re a type 2 person with diabetes, taking basal insulin once or twice daily is a chore. You do it because you have to if you want to maintain your health. You don’t look forward to it, but part of you is always thankful that insulin is available.

 

So how would you feel about a basal insulin that you take once a week? Not daily, and not every other day, but once every seven days?

 

That is an insulin now in development by Novo Nordisk, which already sells insulin degludec (Tresiba®) the longest lasting daily basal on the market (along with Sanofi’s insulin glargine 300, Toujeo®).

 

Called “icodec, the insulin has finished a phase II testing phrase with notable results. The tests involved 247 type 2 patients ages 18 to 75nwho had never previously received basal insulin and had poor glycemic control. All the test participants were taking metformin daily, while some also were taking a DPP-4 inhibitor, such as Januvia®, Tradjenta®, Onglyza®, etc. Their A1c’s ranged from 7.0% to 9.5%.

 

The 26-week test compared glycemic control between patients taking icodec and patients taking insulin glargine U100, the most often prescribed pre-Tresiba®/pre-Toujeo® basal .

 

Test results showed that once-weekly icodec versus daily Lantus showed almost identical results. Patients taking icodec saw their A1c’s drop an average of 1.33%, while patients taking Lantus® saw a 1.15% drop.

 

The mean A1c percentage for the icodec patients was 6.7% compared to 6.9% for Lantus® users. In all, 72 percent of the icodec patients recorded an A1c of less than 7% compared to 68% of Lantus® patients.

These were crucial results since the potential drawback to a once-weekly basal insulin would be a drop off in its performance over the course of 168 hours. Its comparative effectiveness against a daily basal is a good sign that icodec is ready for phase III testing, which will involve a considerably higher number of test patients—a “make or break” segment of drug testing.

 

Hope for the success of a once-weekly basal insulin rests on the expectation that type 2 insulin users would be more inclined to stick to a weekly rather than a daily schedule. Compliance has always been one of healthcare providers’  main concerns when it comes to insulin-using patients.

 

Source:

Rosenstock J, et al “Once-weekly insulin for type 2 diabetes without previous insulin treatment” N Engl J Med 2020; DOI: 10.1056/NEJMoa2022474.

The post Diabetes Health Type 2: Once-Weekly Basal Insulin                                                                                                                                                                                    appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , ,

Diabetes Health in The News Podcast: Medicare Insulin Copayments to Be Reduced by 66%

July 30, 2020By

Click on the arrow to listen to the podcast

Diabetes Health Staff

 

The federal government has taken a big first step at becoming involved in the growing nationwide controversy over soaring insulin prices. And it’s one that will have a significant impact on seniors with diabetes who rely on Medicare for their insulin prescriptions: As of January 2021, Medicare enrollees who have been paying $ 105 in copayments  a month’s for insulin will now be asked to make a $ 35 copayment for their insulin prescription.  That’s a 66-percent reduction in direct costs to the 3 million people on Medicare who need insulin.

Seniors with diabetes who are enrolled in Medicare will enjoy an average annual savings of $ 446 in insulin costs.

The White House, in adding details to its Part D Senior Saving Model that was first announced in March, says that as of late May the program has already attracted 88 health insurers representing 1,750 plans.

Three of the biggest insulin suppliers to U.S. consumers, Eli Lilly, Sanofi, and Novo Nordisk, have all agreed  to increase the discounts they offer for their respective insulin brands.

This won’t be the last we hear about federal attempts to rein in insulin costs, which have increased 200 percent over the past 10 years. Congress has recently begun discussing the high price of insulins as well as various state legislatures.

 

The post Diabetes Health in The News Podcast: Medicare Insulin Copayments to Be Reduced by 66% appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , , ,

Diabetes Health Type 1 &2: Novo’s Weekly Insulin Now in Phase II Testing

July 18, 2020By

Diabetes Health Staff

Even though the annual Scientific Sessions of the American Diabetes Association (June 12-16) will be “virtual,” with presenters and attendees spread around the world and Zooming in via their computers, there are already some tantalizing hints about new drug development.

 Novo Nordisk researchers will present an update on insulin icodec, a long-acting basal insulin they are developing that has a half life of 196 hours—8+ days. The drug, which has now entered phase II* testing, offers the possibility of a once weekly insulin dose for people with type 2 diabetes.

The insulin is very concentrated, which means that even though it is injected once a week, the injection is not a multiple of the volume of daily injections a type 2 takes.

Novo currently is comparing insulin icodec’s performance against insulin glargine U100, Sanofi-Aventis’s Lantus®, which is one of the most prescribed basal insulins in the world.

Icodec will enter a market where Novo and Sanofi are already competing for share with two extremely powerful basal insulins, Tresiba® (insulin degludec) from Novo, and Toujeo® (insulin glargine U300) from Sanofi. Both insulins provide 24-hour effectiveness, and for now are the heaviest hitters in the diabetes drug market.

In a way, insulin icodec is the logical next step in basal insulins. With Tresiba® and Toujeo® emerging as the first 24-hour basals, the only room for improvement and innovation is to introduce even longer lasting drugs.

At this point in icodec’s development, its eventual cost and acceptance by healthcare insurers and providers won’t be determined for at two or three years. Still, it’s something to look forward to for type 2s who are tired of the unrelenting need for daily insulin injections—even ones that can last an entire day.

 

A GLP-1 in Pill Form

Novo also plans to present data on Rybelsus® (semaglutide) is the first GLP-1 receptor agonist in the market. GLP-1s spur type 2 pancreas’s into making more insulin, while at the same time producing fewer incidence of hypoglycemia than, say, sulfonylureas . Rybelsus’s claim to fame is that it is the first GLP-1 to enter the market in pill form (7 mg and 14 mg doses).  Other brands of GLP-1s on the market include, among others, Byetta®, Victoza®, Trulicity®, and Ozempic®.

 

The post Diabetes Health Type 1 &2: Novo’s Weekly Insulin Now in Phase II Testing appeared first on Diabetes Health.

Diabetes Health

Filed Under: Fat Loss Tips Tagged With: , , , , , , ,

New Research Sheds Light on the Effects of Insulin on the Brain

August 8, 2019By

Research out of the University at Albany sheds light on the effects that insulin has on our ability to form new memories and recall old ones
Newswise: Latest News

Filed Under: Fat Loss Tips Tagged With: , , , , ,
Next Page »